The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 07, 2023

Filed:

Jul. 18, 2012
Applicants:

Maged Henary, Lawrenceville, GA (US);

W. David Wilson, Atlanta, GA (US);

Inventors:

Maged Henary, Lawrenceville, GA (US);

W. David Wilson, Atlanta, GA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C09B 23/06 (2006.01); C07D 209/14 (2006.01); C07D 403/06 (2006.01); C07D 213/73 (2006.01); C07D 209/49 (2006.01); C07D 403/12 (2006.01); C07D 407/12 (2006.01); C07D 249/10 (2006.01); C07D 231/14 (2006.01); C07D 413/14 (2006.01); C07D 239/34 (2006.01); C07D 231/20 (2006.01); C07D 401/14 (2006.01); C07D 401/04 (2006.01); C07D 403/10 (2006.01); C07D 209/18 (2006.01); C07D 235/24 (2006.01); C07D 417/12 (2006.01); C07D 213/64 (2006.01);
U.S. Cl.
CPC ...
C09B 23/06 (2013.01); C07D 209/14 (2013.01); C07D 209/18 (2013.01); C07D 209/49 (2013.01); C07D 213/64 (2013.01); C07D 213/73 (2013.01); C07D 231/14 (2013.01); C07D 231/20 (2013.01); C07D 235/24 (2013.01); C07D 239/34 (2013.01); C07D 249/10 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/06 (2013.01); C07D 403/10 (2013.01); C07D 403/12 (2013.01); C07D 407/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01);
Abstract

Cyanines which selectively bind to G-quadruplex DNA complexes, particularly quadruplexes expressed in cancer cells, and methods of making and using thereof are described herein. The cyanine can be a symmetrical or unsymmetrical streptocyanine, hemicyanine, closed chain cyanine, or combinations thereof. The cyanine is preferably substituted with one or more groups that minimize or prevent aggregation of the cyanine and/or inhibit binding of the cyanine to duplex DNA. One or more of the cyanines can be formulated with one or more pharmaceutical excipients and/or carrier to prepare pharmaceutical compositions suitable for administration to a patient, particular a human patient. The compounds and compositions described herein can be used to treat diseases or disorders characterized by the expression of G-quadruplex DNA, such as cancer.


Find Patent Forward Citations

Loading…